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Prognostic biomarkerBackground and purpose: The derived neutrophil–lymphocyte ratio (dNLR) is a validated prognostic bio-
marker for cancer survival but has not been extensively studied in locally-advanced oesophageal cancer
treated with definitive chemoradiotherapy (dCRT). We aimed to identify the prognostic value of dNLR in
patients recruited to the SCOPE1 trial.
Materials and methods: 258 patients were randomised to receive dCRT ± cetuximab. Kaplan–Meier’s
curves and both univariable and multivariable Cox regression models were calculated for overall survival
(OS), progression free survival (PFS), local PFS inside the radiation volume (LPFSi), local PFS outside the
radiation volume (LPFSo), and distant PFS (DPFS).
Results: An elevated pre-treatment dNLR  2 was significantly associated with decreased OS in univari-
able (HR 1.74 [95% CI 1.29–2.35], p < 0.001) and multivariable analyses (HR 1.64 [1.17–2.29], p = 0.004).
Median OS was 36 months (95% CI 27.8–42.4) if dNLR < 2 and 18.4 months (95% CI 14.1–24.9) if
dNLR  2. All measures of PFS were also significantly reduced with an elevated dNLR. dNLR was prognos-
tic for OS in cases of squamous cell carcinoma with a non-significant trend for adenocarcinoma/undiffer
entiated tumours.
Conclusions: An elevated pre-treatment dNLR may be an independent prognostic biomarker for OS and
PFS in oesophageal cancer patients treated with definitive CRT. dNLR is a simple, inexpensive and readily
available tool for risk-stratification and should be considered for use in future oesophageal cancer clinical
trials.
The SCOPE1 trial was an International Standard Randomised Controlled Trial [number 47718479].
 2017 The Authors. Published by Elsevier Ireland Ltd. Radiotherapy and Oncology 125 (2017) 154–159
This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/3.0/).Oesophageal cancer is the 13th most common cancer in the UK
with approximately 8800 new diagnoses each year [1]. Despite
steady improvements in treatment outcomes over the last four
decades, the majority of patients present with advanced disease
and 5-year survival rates remain low at round 15% [1].
The SCOPE1 (Study of Chemoradiotherapy in OesoPhageal Can-
cer with or without Erbitux) trial has standardised radiotherapy
treatment protocols within the UK [2]. The trial was closed at thephase II stage due to higher rates of toxicity and poorer survival
outcomes in patients randomised to CRT with cetuximab [3]. How-
ever the long-term outcomes have demonstrated survival rates
similar to surgical studies, with a median overall survival of
34.5 months (95% CI 24.7–42.3 months) for patients treated with
cisplatin/capecitabine-based CRT [4]. This has added to the grow-
ing evidence that definitive chemoradiotherapy (dCRT) is a compa-
rable curative treatment option in selected patient groups,
particularly in cases of locally advanced squamous cell carcinoma
or if surgery is unfeasible due to extent of disease or patient co-
morbidities [5–7].
In an era of personalised medicine, the use of robust prognostic
factors is being investigated to further improve outcomes as risk-
stratification at the point of diagnosis could allow an appropriate
treatment strategy to be selected for the individual patient [8]. Sys-
temic inflammation is a recognised characteristic of malignancy [9]
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prognostic indicators in cancer patients [10,11].
One such biomarker, the neutrophil–lymphocyte ratio (NLR),
has been associated with reduced survival in many solid tumours
[12,13]. As the differential white cell count is regularly performed
in the management of cancer patients, NLR is a relatively simple
and inexpensive biomarker to implement in routine clinical prac-
tice. However it is a usual practice to only record total white blood
cell (WBC) count and absolute neutrophil count (ANC) in trial data-
bases, which may restrict the wider use of NLR in the clinical trial
setting. As a result a modified version, the derived NLR (dNLR), has
been developed using WBC and ANC parameters and is reported to
have a similar prognostic value to NLR, using an optimal cut-off
value  2:1 [14].
In this study, we investigated the prognostic value of dNLR on
progression-free survival (PFS) and overall survival (OS) in oeso-
phageal cancer patients treated with dCRT in the SCOPE1 (Study
of Chemoradiotherapy in OesoPhageal Cancer with or without
Erbitux) trial. We also aimed to identify the optimal dNLR cut-off
value in this patient group.Materials and methods
Study design and setting
The primary objective of the randomised (1:1) phase 2/3
SCOPE1 study was to compare the effect of CRT with and without
cetuximab on survival in patients with oesophageal cancer deemed
unsuitable for surgery. 258 patients were recruited from 36 centres
in the UK between February 2008 and January 2012. The CRT reg-
imen consisted of 2 cycles of induction cisplatin–capecitabine
chemotherapy followed by a further 2 cycles given concurrently
with conformal external beam radiotherapy (50 Gy in 25 fractions
over 5 weeks) with or without 12 weeks of cetuximab. The SCOPE1
adhered to the rules of CONSORT; the trial design, eligibility crite-
ria and results have been reported previously [3,15]. Written
informed consent was obtained from all recruited patients. A blood
sample was taken in the week prior to starting treatment in all
patients enroled to the trial; WBC and ANC were documented on
the case report form.Statistical methods
All statistical analyses were pre-planned and conducted using
Stata SE 14. We calculated % of total dose (actual total dose divided
by protocol total dose) and % dose intensity (actual dose intensity
[dose per unit time] divided by protocol dose intensity) for each
protocol drug as measures of compliance. As has been done else-
where, patients who progressed or died during the treatment per-
iod had denominators calculated up to the point where they
progressed or died [16]. Likewise for radiotherapy we calculated
% of full protocol dose received by each patient and for those
who progressed or died during the treatment period the denomi-
nator was calculated up to the point where they progressed or
died.




dNLR was redefined as a binary variable by finding the value
from a receiver-operating characteristic (ROC) curve that max-
imised the percentage correctly classified for predicting survival
at 24 months (the median OS found in the first analysis of SCOPE1
[3]). The balance of this binary dNLR variable across prognostic
characteristics of the SCOPE1 patients was assessed using chisquare tests. Kaplan–Meier’s curves were used to display the prog-
nostic value of the binary dNLR variable for different types of sur-
vival measure: overall survival (OS), progression free survival
(PFS), local progression free survival inside the radiation volume
(LPFSi), local progression free survival outside the radiation vol-
ume (LPFSo), and distant progression free survival (DPFS). We cal-
culated survival from date of randomisation to when an event
occurred i.e. progression or any death for PFS, and any death for
overall survival. Patients who were event free were censored at
the time they were last known to be event free. Univariable (the
binary dNLR) and multivariable Cox regression models were used
to assess the prognostic effect of dNLR on the different types of sur-
vival at two time points – pre-treatment (baseline) and following
two cycles of induction chemotherapy prior to dCRT. The multi-
variable models included, in addition to the binary dNLR, SCOPE1
trial arm, age, reason for not receiving surgery, sex, WHO perfor-
mance status at baseline, disease stage, tumour type, radiation
compliance, cisplatin compliance, capecitabine compliance, and
total disease length as covariates, and treating centre as a shared
frailty. Additionally, a Cox model with a treatment–dNLR level
interaction was used to assess whether the treatment effect dif-
fered between the two dNLR groups. In each case, the validity of
the proportional hazards assumption was checked using Cox–
Snell’s residuals and Schoenfeld’s global test.Results
Of the 258 patients recruited into the SCOPE1 trial between
February 2008 and February 2012, 257 had both pre-treatment
WBC and ANC results collected and were used in these analyses.
The median follow-up (IQR) was 46.2 (35.9–48.3) months for sur-
viving patients. The distribution of dNLR was positively skewed
with a median of 1.86 (IQR: 1.46–2.43, range: 0.75–26.00). The
ROC analysis of the sensitivity and specificity of dNLR in predicting
death within 24 months after randomisation was performed on
250 (97.2%) patients (1 patient did not have a pre-treatment dNLR
available and a further 7 were lost to follow-up prior to 24 months)
(Supplemental material, Fig. S1). Using ROC curve analysis, the
optimal dNLR cut-off value was calculated as 2.029 (sensitiv-
ity = 55.75%, specificity = 70.07%) (Supplemental material, Fig. S1).
Patient and tumour baseline characteristics according to dNLR
(< 2 vs.  2) are shown in Table 1. Of the clinicopathological fea-
tures analysed, sex, performance status, and total disease length
were significantly associated with pre-treatment dNLR. However,
if using a Bonferroni correction (p = 0.05/11 = 0.005), only sex
was significantly associated with dNLR.
Kaplan–Meier’s curves according to the pre-treatment dNLR
demonstrated a survival advantage for patients with dNLR < 2
(Fig. 1). Median OS was 36 months (95% CI 27.8–42.4) for patients
with dNLR < 2 and 18.4 months (95% CI 14.1–24.9) for patients
with dNLR  2. An elevated dNLR  2 was significantly associated
with a decreased OS in both univariable analysis (HR 1.74 [95%
CI 1.29–2.35], p < 0.001) and multivariable analysis (HR 1.64
[1.17–2.29], p = 0.004) (Table 2). In subgroup analysis, dNLR  2
was an independent prognostic factor for poor OS in patients with
squamous cell carcinoma (HR = 2.06, 95% CIs: 1.25–3.41, p = 0.005)
but the evidence was weaker for adenocarcinoma/undifferentiated
tumours (HR = 2.52, 95% CIs: 0.88–7.23, p = 0.085) for whom the
sample size was smaller (Supplemental material, Table S1). PFS,
LPFSi, LPFSo and DPFS were all significantly reduced in patients
with dNLR  2 in both univariable and multivariable analyses
(Fig. 1; Supplemental material Table S1).
In the analysis of OS according to arm allocation within the
SCOPE1 trial, dNLR was not predictive for treatment effect (Fig. 2,
Table 3). The addition of cetuximab to CRT was not associated with
Table 1
Characteristics of the study participants, according to baseline dNLR level.
dNLR < 2 (n = 146) dNLR  2
(n = 111)
Test
n % n % Chi square p
SCOPE1 trial arm dCRT only 74 50.7 54 48.6 0.105 0.746
dCRT + cetuximab 72 49.3 57 51.4
Age <65 65 44.5 44 39.6 0.615 0.433
65 81 55.5 67 60.4
Reason for not receiving surgery Patient choice 59 40.4 38 34.2 1.413 0.493
Local extent of disease 68 46.6 54 48.6
Comorbidity/poor PS 19 13.0 19 17.1
Sex Female 77 52.7 36 32.4 10.555 0.001
Male 69 47.3 75 67.6
WHO performance status 0 83 56.8 48 43.2 4.671 0.031
1 63 43.2 63 56.8
Stage I or II 64 43.8 39 35.1 1.988 0.159
III 82 56.2 72 64.9
Tumour type Squamous 111 76.0 77 69.4 1.423 0.233
Adeno/undiff 35 24.0 34 30.6
Full radiation dose Yes 129 88.4 89 80.2 3.275 0.070
No 17 11.6 22 19.8
Cisplatin intensity 75% 107 73.3 75 66.6 0.998 0.318
<75% 39 26.7 36 33.4
Cape/5FU intensity 75% 103 70.6 70 63.1 1.606 0.205
<75% 43 29.5 41 36.9
Total disease length <4 cm 30 20.5 26 23.4 8.672* 0.034
4 to <6 cm 59 40.4 26 23.4
6 to <8 cm 26 17.8 29 26.1
8 cm 31 21.2 30 27.0
(dNLR: derived neutrophil–lymphocyte ratio; dCRT: definitive chemoradiotherapy; WHO: World Health Organisation).
* Chi square test for trend.
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value for interaction of 0.768.
We repeated the multivariable analyses in a sensitivity analysis
that excluded patients who died during treatment (6 patients) and
the findings above were unchanged.
The prognostic value of a repeat dNLR following 2 cycles of
induction chemotherapy but prior to the commencement of dCRT
was also analysed. Of the 258 patients, 7 were lost to follow up
prior to 2 years and 36 had missing pre-CRT WBC or ANC results,
leaving 215 in the analysis. The distribution of dNLR at this time
point was positively skewed with a median of 1.19 (IQR: 0.85–
1.59, range: 0.33–4.86). Using ROC curve analysis, the optimal
dNLR cut-off value for predicting 2 years of survival was calculated
as 1.5 (correctly classified 60.5%) (Supplemental material, Fig. S2).
An elevated dNLR  1.5 was significantly associated with a
decreased OS in univariable analysis (HR 1.56 [95% CI 1.10–2.21],
p = 0.014) but not in multivariable analysis (HR 1.45 [0.99–2.12],
p = 0.054).
Discussion
In this present study, an elevated pre-treatment dNLR was an
independent prognostic biomarker for OS and PFS in oesophageal
cancer patients treated with definitive CRT. dNLR was also signifi-
cantly associated with OS outcomes in patients with squamous cell
carcinoma, and to a lesser extent in adenocarcinoma/undifferenti
ated tumours. Measurement of dNLR following two cycles of
induction chemotherapy (but prior to commencement of dCRT)
was not associated with OS outcomes in multivariable analysis.
Inflammation in the malignant setting is known to promote
both tumorigenesis and disease progression, and reduces response
to systemic treatments [17]. Proctor et al. [14] originally validated
dNLR as an alternative to NLR in a retrospective cohort study of
more than 12,000 cancer patients with a variety of malignancies,
including oesophageal tumours. Baseline dNLR  2 was associatedwith worse overall survival compared to a dNLR < 2 (HR 1.76;
p < 0.001); cancer-specific survival was also reduced (HR 1.83;
p < 0.001) [14]. In the present study, we calculated the
optimal dNLR cut-off value to be 2, externally validating this
threshold level.
The prognostic value of dNLR has since been investigated in sev-
eral malignancies including breast [18], urological [19], colorectal
[20], and upper gastrointestinal tumours [21–23]. However to
our knowledge, our study is the first to investigate the prognostic
role of dNLR in oesophageal cancer.
There is evidence for the use of NLR as a prognostic indicator of
survival in oesophageal cancer. A meta-analysis of over 1500
patients from seven retrospective cohort studies confirmed that
an elevated pre-treatment NLR was prognostic for OS but not
disease-free survival [24]. T3–4 disease and lymph node disease
were also significantly associated with NLR. However the study
included pooled data from largely Asian, retrospective surgical ser-
ies which included the use of both neoadjuvant and adjuvant CRT,
resulting in significant between-study heterogeneity. Furthermore,
the studies included employed a variety of NLR cut-off values rang-
ing between two and five.
The only study to evaluate NLR in oesophageal cancer patients
treated with definitive CRT confirmed that a raised NLR was an
independent prognostic factor for both OS and PFS in 138 patients
[25]. The patient population was similar to that of our study, the
majority having locally-advanced, predominantly inoperable squa-
mous cell carcinoma. However it was a retrospective study, there
were significant differences in the chemotherapy regimens used
and radiotherapy included treating both the primary and involved
nodes up to a total dose of 63 Gy with considerably larger target
volume margins and regional elective nodal irradiation. Further-
more, the median OS for all patients was significantly lower than
that of the SCOPE1 trial, reported at only 19.9 months (range
1.1–97.2) [25]. Despite these differences in regimens and OS
between cohorts, NLR proved to be discriminatory in both the
Fig. 1. Kaplan–Meier’s curves of survival by baseline dNLR.
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Table 2
Univariable and multivariable Cox regression analysis of overall survival.
Variable Category Time (months) Univariable Multivariable
n Median 95% CIs HR 95% CIs p HR 95% CIs p
dNLR dNLR < 2 146 36.0 27.8–42.4 1.00 1.00
dNLR  2 111 18.4 14.1–24.9 1.74 1.29–2.35 <0.001 1.64 1.17–2.29 0.004
Trial arm CRT only 129 34.5 24.7–42.3 1 1.00
CRT + cetuximab 129 24.7 18.6–31.3 1.25 0.93–1.69 0.137 1.18 0.86–1.61 0.318
Age <65 109 36.7 24.9–43.6 1 1.00
65 149 24.5 19.7–30.1 1.36 1.00–1.85 0.047 1.27 0.91–1.77 0.156
Reason no surgery Patient choice 97 31.3 24.0–44.0 1 1.00
Local extent of disease 122 24.7 18.6–34.5 1.2 0.86–1.68 0.276 0.97 0.67–1.42 0.891
Comorbidity/Poor PS 39 31.6 14.8–42.7 1.25 0.81–1.94 0.318 1.05 0.62–1.80 0.849
Sex Female 113 34.6 24.7–48.8 1 1.00
Male 145 24.9 19.6–31.6 1.44 1.06–1.95 0.02 1.23 0.87–1.74 0.248
WHO status 0 131 30.3 24.0–38.4 1 1.00
1 127 24.9 19.2–34.3 1.14 0.84–1.53 0.405 0.95 0.67–1.35 0.776
Stage I or II 103 42.4 31.3–49.9 1 1.00
III 155 24 18.6–26.8 1.65 1.20–2.27 0.002 1.51 1.04–2.20 0.031
Tumour type Squamous 188 28.4 24.0–38.0 1 1.00
Adeno/undiff 70 24.9 15.9–35.1 1.24 0.90–1.72 0.192 1.02 0.68–1.54 0.926
Full radiation dose Yes 217 34.3 25.8–39.1 1 1.00
No 41 10 5.9–18.4 3.19 2.17–4.70 <0.001 2.03 1.20–3.45 0.009
Cisplatin intensity 75% 182 35.9 27.2–42.4 1 1.00
<75% 76 16.2 12.5–20.8 2.18 1.59–2.99 <0.001 1.86 1.16–3.00 0.011
Cape/5FU intensity 75% 172 34.5 25.4–39.4 1 1.00
<75% 86 20 15.4–24.7 1.66 1.22–2.26 0.001 0.85 0.54–1.33 0.470
Total disease length <4 cm 56 36 24.7–58.0 1 1.00
4 to <6 cm 85 37.9 24.0–49.9 0.98 0.63–1.52 0.928 1.07 0.67–1.71 0.768
6 to <8 cm 55 24.9 18.6–40.3 1.46 0.92–2.33 0.107 1.13 0.67–1.92 0.638
8 cm 62 18.4 14.9–27.8 1.84 1.17–2.89 0.009 1.57 0.94–2.62 0.083
Fig. 2. Kaplan–Meier’s curves of SCOPE1 treatment by dNLR.
Table 3
Effect of dNLR in predicting treatment effect.
Time (months) Univariable Multivariable
n Median 95% CIs HR 95% CIs p HR 95% CIs p
dNLR < 2 dCRT only 72 42.0 31.6–47.9 1.00
dCRT + cetuximab 74 28.2 23.2–38.0 1.26 0.82–1.92 0.290 1.23 0.77–1.96 0.382
dNLR  2 dCRT only 57 19.6 14.2–26.7 1.00
dCRT + cetuximab 54 15.9 9.26–26.8 1.37 0.88–2.12 0.159 1.24 0.67–2.28 0.494
(dNLR: derived neutrophil–lymphocyte ratio; dCRT: definitive chemoradiotherapy).
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assessing prognosis in oesophageal cancer patients being consid-
ered for dCRT.
The major implication of dNLR would be to risk-stratify
patients, assisting the clinician and patient to make an informed
decision about treatment options. For example, in patients who
are borderline fit for dCRT, it is often difficult to quantify potential
benefits of a given treatment versus the real risk of significant and
potentially life-threatening toxicities. Discussions using pre-
treatment dNLR results may assist the individual patient to weigh
up whether the side-effects of dCRT are worth risking, particularly
if they are considered to have a poor prognosis as determined by a
raised pre-treatment dNLR, or whether they would prefer to
employ a more conservative treatment strategy. Given the varia-
tion in survival, consideration should also be given to use dNLR
as a stratification factor for future dCRT trials.
The strengths of this current study is that the data were
prospectively collected, in the setting of a randomised controlled
trial which has now standardised treatment of oesophageal cancer
with dCRT in the UK. dNLR was available for all patients within one
week of starting treatment in the patients included in our analysis.
However, the dNLR cut-off value found in this study will need to be
validated in further independent datasets. Whilst this study has
validated pre-treatment dNLR as a potential prognostic biomarker
for oesophageal cancer patients treated with dCRT, analysis of
other haematological components, albumin and other markers of
the systemic inflammatory response such as C-reactive protein
(CRP) was not conducted.
In conclusion, we have demonstrated that an elevated pre-
treatment dNLR is a potential independent prognostic marker for
both OS and PFS in oesophageal cancer treated with dCRT. It serves
as a readily available tool for risk-stratifying patients and should be
considered as a stratification factor in future clinical trials aiming
to optimise non-surgical treatment strategies for locally-
advanced oesophageal cancer.Conflict of interest statement
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